HAS Healthcare Advanced Synthesis SA a annoncé aujourd’hui son projet d’acquisition de Cerbios-Pharma SA, une fusion soutenue par 65 Equity Partners. Cette acquisition permettra aux deux entreprises de combiner leurs forces de production, leur expertise chimique et biologique, leur savoir-faire et leurs capacités technologiques pour devenir un leader international de qualité dans l’industrie des CDMO. La transaction reste soumise aux autorisations réglementaires et fiscales.
HAS et Cerbios, deux entreprises suisses renommées, apportent une grande expertise en matière de production, de chimie et de biologie, une excellence technique et une gamme élargie de services pour répondre aux besoins évolutifs de l’industrie pharmaceutique mondiale. Avec le soutien stratégique de 65 Equity Partners, le nouveau groupe est prêt à croître dans un secteur en pleine expansion, notamment dans les domaines de l’oncologie, de la neurologie, de l’endocrinologie et d’autres domaines thérapeutiques clés.
La fusion reflète les investissements continus réalisés pour garantir l’excellence et le développement technologique. Les deux entreprises resteront guidées par leurs valeurs familiales et leur engagement envers la région du Tessin en Suisse. Les dirigeants de HAS et de Cerbios se montrent enthousiastes quant à cette nouvelle étape, soulignant l’importance de l’opération pour renforcer leur position sur le marché et offrir des solutions innovantes et personnalisées à leurs clients. 65 Equity Partners will work closely with the management to realize this vision and strengthen the group’s position as a leading provider of complex pharmaceutical ingredients.
HAS received advice from Rothschild & Co (financial), Bär & Karrer (legal), and EY (accounting/tax).
65 Equity Partners received advice from UBS AG (financial), Ropes & Gray and Walder Wyss (legal), EY (accounting/tax), Pharmacloud and Guidance Pharm (commercial), JensonR+ (regulatory), and Orbsen (technical).
About HAS Healthcare Advanced Synthesis SA
HAS Healthcare Advanced Synthesis is a CDMO with four decades of international experience. The company offers a full range of customized services, from development to production. HAS Healthcare Advanced Synthesis SA develops and manufactures active pharmaceutical ingredients (APIs), highly potent active pharmaceutical ingredients (HPAPIs), and anticancer compounds.
The production site, founded in 1984, is located in Biasca, Switzerland. The facility is regularly inspected by SwissMedic, the FDA, and other international regulatory agencies. HAS operates specialized production plants with production capacities ranging from hundreds of grams to tens of kilograms for highly potent active ingredients (HPAPIs) and anticancer compounds, and from a few kilograms to several tens of tons of standard active ingredients (APIs). These plants are dedicated to production in compliance with GMP standards.
For more information, visit our website at https://www.hashealthcare.com/ and follow us on Linkedin.
About Cerbios-Pharma SA
Cerbios-Pharma SA (Cerbios) has nearly 50 years of experience in the industry and expertise in the development and manufacturing of generic APIs, as well as offering CDMO services, manufacturing APIs, HPAPIs, ADCs, and biological probiotics for the international human and animal markets.
Cerbios has two production sites in Switzerland (Lugano, headquarters, and Couvet). Both facilities are regularly inspected by SwissMedic, the FDA, and other international regulatory agencies. Cerbios has a specialized presence in the market as a CDMO service provider, with dedicated production plants.
For more information, visit our website at https://www.cerbios.ch/ and follow us on LinkedIn.
About 65 Equity Partners
65 Equity Partners is an international investment company that partners with founders, families, and entrepreneurs in Europe, North America, and Asia to create long-term sustainable value. We invest in leading companies in the healthcare, industry, business services, technology, and consumer sectors.
Backed by Temasek as an independently managed investment platform with $3.3 billion in assets under management, we provide equity and structured capital solutions to established companies with regional or global growth ambitions. With offices in London, Singapore, New York, and San Francisco, we leverage our local roots, international network, and deep expertise in our extended ecosystem.
For more information, visit our website at https://www.65equitypartners.com/ and follow us on LinkedIn.
Contact Information:
HAS Healthcare Advanced Synthesis SA
Biasca, Switzerland
Press Contact: Giacomo Braglia
Phone: +41 (0) 91 873 94 00
Email: [email protected]
65 Equity Partners
Greenbrook
Contact: Peter Hewer, Theo Bryan, Long Tran
Email: [email protected]
Logos:
65 Equity Partners Logo
HAS Logo
Cerbios Logo
In conclusion, the collaboration between 65 Equity Partners, HAS Healthcare Advanced Synthesis SA, and Cerbios-Pharma SA showcases a commitment to innovation and excellence in the pharmaceutical industry. By leveraging their expertise and resources, they aim to enhance their competitive edge and contribute to the advancement of healthcare globally. For more updates and insights, visit their respective websites and stay connected on social media. The following content will be rewritten:
